Literature DB >> 3198696

Estramustine binds MAP-2 to inhibit microtubule assembly in vitro.

M E Stearns1, K D Tew.   

Abstract

We have investigated the ability of estramustine to bind to rat brain microtubule-associated proteins (MAPs) and purified MAP-2 in vitro. [3H]estramustine's relative affinity for tubulin and MAPs was assessed by gel filtration chromatography, immunoprecipitation and binding assays. Scatchard analysis demonstrated a specific affinity of the drug for MAP-2. Calculations from kinetic parameters and non-linear regression analysis gave a Kd of 15 microM, and a Bmax of 3.4 x 10(-7)M ml-1. Extrapolation of this value suggested that each MAP-2 molecule binds approximately 20 molecules of estramustine. Microtubule assembly studies and SDS-polyacrylamide gel electrophoresis revealed that at 20-60 microM levels, estramustine inhibited the association of MAPs with taxol microtubules. Turbidity (A350) studies further demonstrated that 20-60 microM-estramustine inhibited MAP-2-driven tubulin assembly and produced microtubule disassembly. Electron-microscopic studies confirmed the centrifugation and turbidity results. The data demonstrated that estramustine can bind MAPs and MAP-2 specifically, thereby inhibiting microtubule assembly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198696     DOI: 10.1242/jcs.89.3.331

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  10 in total

Review 1.  High-Mr microtubule-associated proteins: properties and functions.

Authors:  G Wiche
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

2.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.

Authors:  D Panda; H P Miller; K Islam; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 4.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

6.  Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy.

Authors:  J M Piepmeier; P E Pedersen; D Yoshida; C Greer
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

7.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.

Authors:  R J D'Amato; C M Lin; E Flynn; J Folkman; E Hamel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

9.  Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.

Authors:  M E Stearns; M Wang; K D Tew; L I Binder
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

10.  Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.

Authors:  A T Bergenheim; P O Gunnarsson; K Edman; E von Schoultz; M I Hariz; R Henriksson
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.